Chiesi chipped in as the drug discovery platform developer closed a series B round that will fund its expansion into the agrochemical industry.

Sana Biotechnology has closed its first round with more than $700m after investors including GV swung behind its vision to commercialise cell therapies.

Repare Therapeutics, which is commericalising precision cancer drugs based on research at UofT and NYU, added $33m to its IPO after its shares rose 65% post-offering.

Forma Therapeutics, whose investors include Eli Lilly and Novartis, has closed its IPO after seeing its shares double in price.

The home care provider has closed a round led by Optum Ventures and backed by Humana and Echo Health Ventures at approximately $136m.

Celgene Switzerland and BMS-backed precision cancer drug developer Repare Therapeutics added $33m to its IPO after its shares rose 65% post-offering.

MemorialCare Innovation Fund contributed to a series D round that brought the heart valve technology developer's overall funding to more than $36m.

MemorialCare Innovation Fund contributed to a series D round that brought the Caltech spinout's overall funding to more than $36m.

Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.